Search
Clinician Ordering Portal
Scientific Evidence
Atypical melanocytic proliferation on sensitive preauricular check
Jun 2023
Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.
Abnormally pigmented lesion with uncertain malignant potential
Jun 2023
With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.
Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies
Mar 2023
Independent multi-center study demonstrates risk-aligned treatment plans guided by DecisionDx-Melanoma lead to better patient outcomes.
Publication: Archives of Derm Research
The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study
Jan 2023
DecisionDx-Melanoma test results influenced 85% of clinicians’ decisions regarding the SLNB surgical procedure. Use of the test results could help avoid unnecessary procedures in low-risk patients whose tumor biology indicates they could safely forgo the procedure.
Publication: Current Medical Research and Opinion
Incorporating prognostic gene expression profile assays into the management of cutaneous melanoma: an expert consensus panel report
Jan 2023
Expert panel of 6 key opinion leaders in dermatology consensus panel unanimously approved eleven usage guidelines and consensus supporting statements for the appropriate use of GEP testing.
Publication: SKIN: Journal of Cutaneous Melanoma
Improved prognostic guidance by the 31-gene expression profile test for clinical decisions after a negative lymph node for patients with cutaneous melanoma
Jan 2023
Using 31-GEP results to guide clinical management and surveillance based on personalized risk of MSS can direct care, improving patient outcomes.
Publication: Poster, presented at Winter Clinical Dermatolog conference- Hawaii Jan 13-18 2023
The integrated 31-gene expression profile (i31-GEP) test for cutaneous melanoma outperforms a clinicopathologic-only nomogram at identifying patients who can forego sentinel lymph node biopsy
Nov 2022
Comparison of the i31-GEP for SLNB to the MIA nomogram in patients with T1-T2 tumors with complete data (n=582). The precision of each tool to identify patients with <5% SLN positivity risk was analyzed using 95% confidence intervals.
Publication: SKIN: Journal of Cutaneous Melanoma
The integrated 31-gene expression profile test (i31-GEP) for cutaneous melanoma outperforms the CP-GEP at identifying patients who can forego sentinel lymph node biopsy when applying NCCN guidelines
Nov 2022
Study compared the i31-GEP for SLNB with the CP-GEP to identify patients who can safely forego SLNB.
Publication: SKIN: Journal of Cutaneous Melanoma
Improving patient selection for adjuvant therapy: considerations for the role of the 31-gene expression profile test
Oct 2022
Utilizing patient data provided through collaboration with the NCI SEER program in patients with Stage I-III CM, 31-GEP class result was a significant independent predistor of both MSS and OS. Patients with 31-GEP results in addition to clinicopathologic factors had improved survival.
Publication: Poster, presented at the Society for Melanoma Research Conference, Edinburgh Scotland, October 17-20 2022
Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test
Jul 2022
Validation of the integration the 31-GEP testing with clinpath features for invidialized risk assessment of MSS, DMFS, and RFS.
Publication: Journal of the American Academy of Dermatology
Development and validation of a nomogram incorporating gene expression profiling and clinical factors for accurate prediction of metastasis in patients with cutaneous melanoma following MOHS micrographic surgery
Apr 2022
Prospective multicenter study showed that integration of 31-GEP and T stage can gain clinically useful prognostic information from data obtained noninvasively.
Publication: Journal of the American Academy of Dermatology
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th edition staging
Apr 2022
DecisionDx-Melanoma data significantly stratified MSS in stage I, II, and III patients. This test has also demonstrated high specificity and NPV for melanoma-specific mortality (MSM).
Publication: Melanoma Research